A Phase Ii Study Assessing The Benefit Of Cisplatin Re-Introduction (Stop And Go Strategy) In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (Nsclc): The Ifct-1102 Bucil Study (A Better Use Of Cisplatin In Lung Cancer).

Fabrice Barlesi,Judith Raimbourg,Pascal Do,Patrick Dumont,Jacques Cadranel,Didier Debieuvre,Werner Hilgers,Pierre Jean Souquet,Olivier Molinier,Elisabeth A. Quoix,Alexandra Langlais,Marie Paule Lebitasy,Franck Morin,Gerard Zalcman,Jaafar Bennouna,French Cooperative Thoracic Intergroup

JOURNAL OF CLINICAL ONCOLOGY（2016）

引用 1|浏览1

暂无评分

摘要

9077Background: Pemetrexed (Pem) + Cisplatine (Cis) + Bevacizumab (Bev) followed with maintenance therapy (Bev and/or Pem) is a therapeutic standard in advanced non-squamous NSCLC. Methods: A singl...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要